Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Leqembi
Biogen's monoclonal antibody for Alzheimer's disease.
Biotech
Lilly glides out of Leqembi slipstream with FDA meeting request
If you thought that Eli Lilly's donanemab could ensure a smooth regulatory flight in the slipstream of Eisai and Biogen, the FDA has other ideas.
Annalee Armstrong
Apr 17, 2024 5:00am
FDA revises guidance on predicting Alzheimer's drug benefits
Mar 12, 2024 7:40am
Lilly's donanemab delayed as FDA seeks late advisory meeting
Mar 8, 2024 8:27am
Biogen's future Alzheimer's pipeline forms around tau, orals
Mar 7, 2024 10:25am
Eisai’s Cheung takes top spot at NextPoint Therapeutics
Feb 1, 2024 10:40am
Scientists reflect on Roche's Alzheimer's failure a year later
Nov 15, 2023 5:00pm